<DOC>
	<DOCNO>NCT00735345</DOCNO>
	<brief_summary>The aim study evaluate feasibility safety chemotherapy induction treatment combine cetuximab follow chemoradiotherapy combine cetuximab treatment patient non-metastatic esophageal cancer .</brief_summary>
	<brief_title>Chemotherapy Induction Chemoradiotherapy Patients With Esophageal Carcinoma</brief_title>
	<detailed_description>Patients locoregional carcinoma esophagus gastro-esophageal junction low survival prognosis follow surgical resection . In study publish date positive effect upon overall survival could demonstrate preoperative chemotherapy chemoradiotherapy . However , patient complete remission follow preoperative therapy show prolong survival . This study design base upon decrease primary tumour prevent oder delay micrometastases mean chemo induction therapy , increase R0 resection rate prevent local recurrence mean preoperative chemoradiotherapy , increase radiosensitivity tumour cell treatment combination cetuximab , surgical resection locoregional primary tumour definitive radiochemotherapy case primary tumour inoperable . The aim study therefore evaluate feasibility safety 3-staged therapy approach include EGFR antibody treatment patient potentially resectable esophageal cancer , well evaluation objective response rate preoperative therapy .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Signed informed consent histologically confirm esophageal cancer ( squamous cell carcinoma ) measurable , nonmetastatic disease ( uT14 ) previous cancer therapy ( chemotherapy , radiotherapy resection ) life expectancy &gt; 3 month age &gt; 18 year WHO Status ≤ 2 negative pregnancy test woman childbearing potential , use adequate contraception hematological status : neutrophile ≥ 1,5x10E9/L , thrombocytes ≥ 100x10E9/L adequate renal function : serum creatinine ≤ 1,5 x ULN adequate liver function : alkaline phosphatase &lt; 2,5 x ULN , total bilirubin &lt; 1,5 x ULN pregnant nursing woman woman childbearing potential without adequate contraception concomitant antitumoral therapy except study mandate procedure cervical esophageal cancer diagnosis metastases participation clinical trial within last 30 day history malignant disease within last 5 year peripheral neuropathy ( NCI CTC ≥ grade 1 ) concurrent active serious nonmalignant disease : uncontrolled heart insufficiency , angina pectoris , hypertension arrhythmia , liver disease , significant neurological psychiatric condition active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Esophageal cancer</keyword>
	<keyword>Pre-operative</keyword>
	<keyword>Chemo-immunotherapy</keyword>
	<keyword>Radiochemo-immunotherapy</keyword>
	<keyword>EGFR</keyword>
	<keyword>Radiosensitivity</keyword>
	<keyword>Resection</keyword>
</DOC>